Hexagon Bio, a biotech startup that studies fungus for potential medicinal uses, raised $47 million in its Series A funding round. With the new capital it will move forward with its drug discovery research.
Drug development startup Hexagon Bio raises $47M
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.